An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases§


  • Potential conflict of interest: Dr. Nelson receives research support from Vertex, Merck, Phamassett, Genentech/Roche, Gilead, Bristol-Myers Squibb, Tibotec, Bayer/Onyx and serves on advisory boards of Merck, Pharmassett, Genentech/Roche, Gilead, Tibotec, and Bayer/Onyx, and is a consultant for Vertex.

    Dr. Thomas receives research support from Merck, Gilead and serves on a Merck advisory board.

    Dr. Ghany, Dr. Seeff, and Dr. Strader have nothing to report.

  • Consultant in Hepatology for the U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20943. The views expressed in the document are those of the authos and not of the Food and Drug Administration.

  • §

    All AASLD Practice Guidelines are updated annually. If you are viewing a Practice Guideline that is more than 12 months old, please visit for an update in the material.